In vitro growth-inhibitory effects of Portulaca oleracea L. formulation on intestinal pathogens

References

1. Jialin T. Chinese Materia Medica China: People’s Medical Publishing House; 2007
   [Google Scholar]
2. von Seidlein L, Kim DR, Ali M, Lee H, Wang X et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Med 2006; 3:e353 [View Article] [PubMed]
   [Google Scholar]
3. WHO Who cholera fact sheet,; 2017
4. Bielaszewska M, Idelevich EA, Zhang W, Bauwens A, Schaumburg F et al. Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. Antimicrob Agents Chemother 2012; 56:3277–3282 [View Article] [PubMed]
   [Google Scholar]
5. Herold S, Karch H, Schmidt H. Shiga toxin-encoding bacteriophages--genomes in motion. Int J Med Microbiol 2004; 294:115–121 [View Article] [PubMed]
   [Google Scholar]
6. Atia A, Buchman AL. Treatment of cholera-like diarrhoea with oral rehydration. Ann Trop Med Parasitol 2010; 104:465–474 [View Article] [PubMed]
   [Google Scholar]
7. IDSA Antibiotic resistance fact sheet,; 2013
8. Sur D, Manna B, Niyogi SK, Ramamurthy T, Palit A et al. Role of probiotic in preventing acute diarrhoea in children: a community-based, randomized, double-blind placebo-controlled field trial in an urban slum. Epidemiol Infect 2011; 139:919–926 [View Article] [PubMed]
   [Google Scholar]
9. Murakami J, Kishi K, Hirai K, Hiramatsu K, Yamasaki T et al. Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli O157:H7 in vitro. Int J Antimicrob Agents 2000; 15:103–109 [View Article] [PubMed]
   [Google Scholar]
10. Seyama S, Nishioka H, Nakaminami H, Nakase K, Wajima T et al. Evaluation of in vitro bactericidal activity of 1.5% Olanexidine gluconate, a novel biguanide antiseptic agent. Biol Pharm Bull 2019; 42:512–515 [View Article] [PubMed]
    [Google Scholar]
11. Yamada T, Wajima T, Nakaminami H, Kobayashi K, Ikoshi H et al. The modified Gingyo-san, a Chinese herbal medicine, has direct antibacterial effects against respiratory pathogens. BMC Complement Altern Med 2016; 16:463 [View Article] [PubMed]
    [Google Scholar]
12. Rahimi VB, Ajam F, Rakhshandeh H, Askari VR. A pharmacological review on Portulaca oleracea L.: focusing on anti-inflammatory, anti- oxidant, immuno-modulatory and antitumor activities. J Pharmacopuncture 2019; 22:7–15 [View Article] [PubMed]
    [Google Scholar]
13. Zhou Y-X, Xin H-L, Rahman K, Wang S-J, Peng C et al. Portulaca oleracea L.: a review of phytochemistry and pharmacological effects. Biomed Res Int 2015; 2015:92563111 [View Article] [PubMed]
    [Google Scholar]
14. Lei X, Li J, Liu B, Zhang N, Liu H. Separation and Identification of Four New Compounds with Antibacterial Activity from Portulaca oleracea L. Molecules 2015; 20:16375–16387 [View Article] [PubMed]
    [Google Scholar]
15. Jackson JJ, Kropp H. Beta-Lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime. J Infect Dis 1992; 165:1033–1041 [View Article] [PubMed]
    [Google Scholar]
16. Ochoa TJ, Chen J, Walker CM, Gonzales E, Cleary TG. Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli . Antimicrob Agents Chemother 2007; 51:2837–2841 [View Article] [PubMed]
    [Google Scholar]
17. Wajima T, Kinugawa R, Yamada T, Ikoshi H, Noguchi N. Panax notoginseng extract possesses significant antibacterial activity against pathogenic streptococci. Pharmacology 2019; 103:221–227 [View Article] [PubMed]
    [Google Scholar]